Pulmonary Hypertension in Cancer Patients Treated with Tyrosine Kinase Inhibitors

Cancer patients are at increased risk for pulmonary arterial hypertension (PAH) due to the disease itself, chemo- or radiation therapy, pulmonary embolism, or comorbidities. Several tyrosine kinase inhibitors (TKIs), which are increasingly used in the treatment of various cancers, have been linked with PAH. We aimed to describe the incidence of PAH triggered or worsened by tyrosine kinase inhibitors (TKIs) in patients with chronic myelogenous leukemia (CML).

Source: Journal of Cardiac Failure - July 31, 2019 Category: Cardiology Authors: Soumya Patnaik, Lissette R. de Armas, Dana E. Giza, Dinu V. Balanescu, Teodora Donisan, Juan Lopez-Mattei, Peter Kim, Gloria Iliescu, Kara Thompson, Elie Mouhayar, Naval Daver, Jean-Bernard Durand, Jorge E. Cortes, Cezar Iliescu Tags: 414 Source Type: research